Showing 3721-3730 of 7858 results for "".
- New Data for Lebrikizumab and Tildrakizumab Unveiled at ICD 2025https://practicaldermatology.com/news/new-data-for-lebrikizumab-and-tildrakisumab-unveiled-at-icd-2025/2475320/New real-world and clinical data supporting the use of lebrikizumab in atopic dermatitis (AD) and tildrakizumab in psoriasis was recently presented at the XIV International Congress of Dermatology (ICD) in Rome, according to a press release from Almirall.
- Study: Cost of AD Care Higher in Low-Income Areashttps://practicaldermatology.com/news/study-cost-of-ad-care-higher-in-low-income-areas/2475282/Recommended skin care products for atopic dermatitis (AD) were found to be more expensive and less accessible in lower-income neighborhoods, new research in the Journal of Drugs in Dermatology indicates. "Pharmacy des
- Elevated IFN Signatures Seen in Nonlesional Skin of Cutaneous Lupus Erythematosus Patientshttps://practicaldermatology.com/news/elevated-ifn-signatures-seen-in-nonlesional-skin-of-cle-patients/2475210/Patients with systemic lupus erythematosus (SLE) and a history of cutaneous lupus erythematosus (CLE) showed elevated interferon-stimulated gene (ISG) expression in blood and nonlesional skin, according to a new study. The si
- Coverage Decision May Jeopardize Image-guided Skin Cancer Treatment: Reporthttps://practicaldermatology.com/news/medicare-contractors-threaten-coverage-of-noninvasive-skin-cancer-treatment/2475193/Medicare Administrative Contractors (MACs) are proposing to withdraw insurance coverage for image-guided superficial radiation therapy (IGSRT), according to a news letter from SkinCure Oncology. IGSRT is an FDA-cleared, nonin
- GALDA Co-Director Explains Organization's Work and Impacthttps://practicaldermatology.com/news/GALDA-Co-Director-Explains-Organizations-Work-Impact/2475171/The Gay and Lesbian Dermatology Association (GALDA) is an organization of dermatologists and health-care professionals dedicated to unity and networking of the gay community at dermatology meetings. For Pride Month, we spoke with GALDA co-director William L Waller III, MD, FAAD, to learn more abo
- New IL-13/IL-31R Bispecific Antibody Data Presented at EAACIhttps://practicaldermatology.com/news/New-IL-13-IL-31R-Bispecific-Antibody-Data-Presented-EAACI/2475170/A new IL-13/IL-31R bispecific antibody demonstrated ability to simultaneously suppress the inflammatory and pruritogenic pathways in atopic dermatitis (AD), according to preclinical study data presented at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 in Glasgow, S
- Bimekizumab 3-Year Data Shows Lasting Efficacy, Control of Inflammation for PsA, axSpAhttps://practicaldermatology.com/news/Bimekizumab-3-Year-Data-Shows-Lasting-Efficacy-Control-Inflammation-PsA-axSpA/2475126/Bimekizumab (BIMZELX®) demonstrated sustained control of inflammation and deep efficacy in patients living with psoriatic arthritis (PsA) and active axial spondyloarthritis (axSpA), according to new 3-year data from phase 3 trials and open-label extensions in adults with active PsA and active axS
- INTEGUMENT-INFANT to Test Roflumilast Cream in Children Under Twohttps://practicaldermatology.com/news/integument-infant-to-test-roflumilast-cream-in-children-under-two/2475087/Arcutis Biotherapeutics has announced the enrollment of the first participants in its new phase 2 INTEGUMENT-INFANT study focusing on the safety and tolerability of ZORYVE (roflumilast) cream 0.05% in infants with atopic dermatitis (AD).
- INT for Melanoma 'Coming Very Fast,' Dr. Joel Claveau Says at Noah Worcester Meetinghttps://practicaldermatology.com/news/INT-Melanoma-Coming-Very-Fast-Dr-Joel-Claveau-Says-Noah-Worcester-Meeting/2475044/The next big thing in melanoma treatment may be individualized neoantigen therapy (INT)—according to Joel Claveau, MD, in a presentation at the Noah Worcester Dermatological Society meeting in Quebec City, Quebec. “It’s almost rocket science, but it’s really coming very fast,” Dr. Claveau
- The Future of Psoriasis: Improving Efficacy, Access, and Morehttps://practicaldermatology.com/news/Future-Psoriasis-Improving-Efficacy-Access-More/2475040/The biologic revolution in psoriasis may only be getting started. In a presentation at the Noah Worcester Dermatological Society meeting in Quebec City, Quebec, Ronald Vender, MD, made eight predictions for the future of psoriasis treatments, with impacts ranging from efficacy to affordabi